Education
About Us
Working with TipRanks
Follow Us
Alkermes plc (ALKS)
:ALKS
ALKS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.56 - $36.45
Previous CloseN/A
Volume176.14K
Average Volume (3M)1.87M
Market Cap
$4.67B
Enterprise Value$3.87B
Total Cash (Recent Filing)$399.81M
Total Debt (Recent Filing)$74.10M
Price to Earnings (P/E)13.6
Beta0.80
Next Earnings
Oct 22, 2025EPS Estimate
0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.67
Shares Outstanding165,077,970
10 Day Avg. Volume1,276,877
30 Day Avg. Volume1,874,199
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit2.92
Enterprise Value/Ebitda8.65
Forecast
1Y Price Target
$38.65Price Target Upside36.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
Bulls Say, Bears Say
Bulls Say
Financial GuidanceManagement reiterated its FY25 financial guidance, indicating confidence in future performance.
Product EfficacyThe success in meeting Epworth Sleepiness Scale (ESS)—a key secondary endpoint measuring daytime sleepiness—across all doses further underscores alixorexton’s potential to treat the hallmark symptom of NT1.
Sales PerformanceAlkermes reported 2Q net sales of $307M, representing a 14% increase driven by growth demand for all three products, as well as one-time positive gross-to-net adjustments during this quarter that provided a $20M tailwind.
Bears Say
Cataplexy DataThe lack of statistically significant effect on weekly cataplexy rate for two doses is perplexing.
Data DisclosureInvestors tend to think more negatively when they don’t get the details in the first press release, which explains why the stock is down.
Market ReactionThe negative stock reaction for ALKS was in response to the limited disclosure around the Ph 2b NT1 data, which led to more questions than answers.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.56 and its highest was $36.45 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $4.67B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Oct 22, 2025 which is in 67 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on Jul 29, 2025. The company reported $0.668 earnings per share for the quarter, beating the consensus estimate of $0.356 by $0.312.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is 0.4.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 165,077,970 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of $0.668 in its last earnings report, beating expectations of $0.356. Following the earnings report the stock price went up 3.25%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
Alkermes Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.65 (36.77% Upside)
$38.65 (36.77% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.41%
12-Months-Change
Fundamentals
Return on Equity
23.94%
Trailing 12-Months
Asset Growth
2.08%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Company Deck
ALKS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Alkermes highlighted strong financial performance and promising clinical trial results for alixorexton, particularly in addressing wakefulness, fatigue, and cognition in narcolepsy type 1. However, increased R&D expenses and uncertainty regarding the cataplexy data, alongside market concerns about visual adverse events, present challenges. Despite these, the overall sentiment is positive due to the company's financial strength and clinical progress.View all ALKS earnings summariesALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$38.65
▲(36.77% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Blueprint Medicines
―
Axsome Therapeutics
―
Krystal Biotech
―
Ownership Overview
1.41% Insiders
31.30% Mutual Funds
0.47% Other Institutional Investors
36.32% Public Companies and
Individual Investors